Emerging studies suggest Retatrutide , a dual activator targeting both GLP-1 and GIP , appears to provide a notable development for obesity loss . Preliminary human tests have demonstrated substantial losses in body tissue, possibly surpassing current weight-loss medications . Nevertheless , more